Keywords: Novelos, Lung cancer, NOV-002, Research
Novelos shares slump 82% as pivotal Ph III lung cancer trial fails to meet primary survival endpoint
Article | 25 February 2010
Massachusetts, USA-based Novelos Therapeutic saw its share price plummet 82% to just $0.30, after the company announced that the primary endpoint of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
